EDG-5506 Dose 1 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 113 | 筋ジストロフィー | 2 |
113. 筋ジストロフィー
臨床試験数 : 646 / 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05540860 (ClinicalTrials.gov) | October 24, 2022 | 6/9/2022 | A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy | A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B | Duchenne Muscular Dystrophy | Drug: EDG-5506 Dose 1;Drug: EDG-5506 Dose 2;Drug: EDG-5506 Dose 3;Drug: Placebo | Edgewise Therapeutics, Inc. | NULL | Recruiting | 4 Years | 9 Years | Male | 27 | Phase 2 | United States |
| 2 | NCT05291091 (ClinicalTrials.gov) | July 6, 2022 | 14/3/2022 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (CANYON) | A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy | Becker Muscular Dystrophy | Drug: EDG-5506 Dose 1;Drug: EDG-5506 Dose 2;Drug: EDG-5506 Dose 3;Drug: EDG-5506 Dose 4;Drug: EDG-5506 Dose 5;Drug: Placebo | Edgewise Therapeutics, Inc. | Medpace, Inc. | Recruiting | 12 Years | 50 Years | Male | 66 | Phase 2 | United States;Netherlands;United Kingdom |